Astrocyte and Microglial Disparities in PI3K/AKT Signaling: Implications for Parkinson's Disease Inflammation

Parkinson's Disease (PD), following Alzheimer's Disease, is the second most prevalent neurological condition globally. This progressive disorder is characterized by the loss of dopaminergic neurons in the substantia nigra, leading to motor dysfunction. Neuroinflammation, a complex process involving astrocytes and microglia, significantly contributes to PD pathogenesis. The PI3K/AKT signaling pathway, a pivotal regulator of cell survival and function, is dysregulated in PD. While it can exert neuroprotective effects, it can also be neurotoxic under certain conditions. Astrocytes, the most abundant glial cells in the central nervous system (CNS), can both promote neuronal survival by releasing neurotrophic factors and modulate synaptic activity. However, they can also contribute to neurodegeneration by releasing inflammatory mediators and reactive oxygen species (ROS). Microglia, the resident immune cells of the CNS, play a dual role. They can phagocytose damaged neurons and debris, but they can also release pro-inflammatory cytokines and chemokines, exacerbating neuroinflammation. Understanding the intricate interplay between the PI3K/AKT signaling pathway, astrocytes, and microglia in PD is crucial for developing novel therapeutic strategies. Targeting these pathways may hold promise for mitigating neuroinflammation, enhancing neuronal survival, and improving outcomes for patients with PD.